NIDA INVEST Postdoctoral Fellowship International Scholars |
|
|
Special Application Deadline: April 1, 2023
NIDA International Program is accepting applications for international postdoctoral researchers for the INVEST Drug Use and Addiction Research Fellowship. This combines postdoctoral research training in the United States with professional development activities and grant-writing guidance to form a unique program for drug use and addiction scientists.
Fellowship: The 12-month INVEST fellowship provides rigorous postdoctoral research training with a NIDA grantee at a U.S. institution, professional development activities that help establish personal relationships with NIDA grantees and NIDA officials, a stipend for living and personal expenses, and an allowance to cover the cost of health insurance and professional development activities.
Eligibility: INVEST applicants are required to be international researchers with a doctoral degree and a minimum of 2 years of postdoctoral experience, to have citizenship or permanent residency in a country other than the United States, and to have a proficiency in written and spoken English.
INVEST Mentors: INVEST mentors must be NIDA-funded researchers in the United States. Their NIDA-funded grants must be active throughout the proposed fellowship period.
Reference: Steven W. Gust, Judy McCormally, & Nei-Hyun Park (2021). Increasing evidence-based substance use interventions globally: The National Institute on Drug Abuse postdoctoral fellowships, Substance Abuse, 42(4):397-406, https://doi.org/10.1080/08897077.2021.1975874.
Contact NIDA: For questions about the INVEST Postdoctoral Fellowship, contact ip@nida.nih.gov. · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · ·
X-Waiver No Longer Required for Buprenorphine Prescribing for OUD
On December 29, 2022, with the signing of the Consolidated Appropriations Act of 2023 (the Act), Congress eliminated the "DATA-Waiver Program." The DEA sent a notice to DEA registrants that stated:
DEA fully supports this significant policy reform. In this moment, when the United States is suffering tens of thousands of opioid-related drug poisoning deaths every year, the DEA’s top priority is doing everything in our power to save lives. Medication for opioid use disorder helps those who are fighting to overcome opioid use disorder by sustaining recovery and preventing overdoses. At DEA, our goal is simple: we want medication for opioid use disorder to be readily and safely available to anyone in the country who needs it. The elimination of the X-Waiver will increase access to buprenorphine for those in need.
Read the full DEA notice here. |
CTN Trial Progress
 Randomizations for Active Studies as of the February 15 Trial Progress Report.
CTN-0080 - Enrolled 127
CTN-0098 - Enrolled 118
CTN-0099 - Enrolled 1387
CTN-0099-A-1 - Enrolled 96
CTN-0100
Discontinuation - Enrolled 117
Retention - Enrolled 687
CTN-0101 - Enrolled 192
CTN-0107 - Enrolled 114
CTN-0108 - Enrolled 75
|
· · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · ·
· · · · · · · · · · · · · · · · · · · · · · ·
Save the Date & Call for Posters: CTN Steering Committee Meeting, April 2023
 Save the Date
The 2023 CTN Steering Committee meeting will be held at the Bethesda North Marriott Hotel & Conference Center (North Bethesda, MD) on April 24-26, 2023.
More information on registration and logistics coming soon!
Call for Posters (In-Person and Virtual): Deadline March 7
Sharing of the results, experiences, techniques, and observations from performing our trials is a critical and exciting part of the CTN experience. To that end, CTN members are encouraged to submit posters for display at the 2023 CTN Annual Steering Committee Meeting Poster Session to be held on April 24, 2023. Poster submissions should be relatable to the CTN either directly (i.e. reporting on CTN studies, data, etc.) or indirectly (i.e. information that informs potential future CTN projects). As in previous years, we will consider new posters as well as posters that were presented at meetings over the past year.
Event: CTN Annual Steering Committee Meeting Poster Session
Venue: Bethesda North Marriott Hotel & Conference Center (North Bethesda, MD)
Date: Monday, April 24, 2023
Time: 5:30 - 7:30 p.m. ET
Guidelines:
- Proposals for new posters should include the title, author list, and brief abstract.
- Proposals for previously presented posters should include the title, author list, name/date of the previous meeting, and an electronic copy of the poster.
- Preference for proposals that indicate that one or more authors will be available to stand with the poster for an hour during the poster session.
- Poster proposals can be submitted here.
- The deadline for submissions is March 7, 2023.
- Presenters are responsible for bringing the poster for display. LMCi will provide 4’h x 6’w posterboards along with pushpins and Velcro.
· · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · ·
· · · · · · · · · · · · · · · · · · · · · · ·
Journal of Substance Use and Addiction (JSAT) Journal Updates
 JSAT Changes Its Name
JSAT has formally changed its name to eliminate the stigmatizing term "abuse" from its title. The new title is "Journal of Substance Use and Addiction Treatment." The journal will still use the abbreviation JSAT. Read more about the name change.
New Monthly Section for Lived Experience
JSAT is adding a new monthly recurring section called "Lived Experience" that seeks short, narrative, non-fiction pieces that will help amplify the voices of people, families, researchers, and clinicians affected by substance use disorder (SUD) and its treatment. Find out more here!
Recruiting Editorial Fellows
Applications are now being accepted for the JSAT Editorial Fellowship Program. Supported by Elsevier and JSAT, the Fellowship is a two-year experience that will begin in July 2023. The fellowship pays an honorarium of $1,000 per person per year. Find out more here!
· · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · ·
· · · · · · · · · · · · · · · · · · · · · · ·
CTN Youth SIG Webinar
 Missing the Mark: Medication Access in Specialty Addiction Settings for Youth with Opioid Use Disorder
March 17, 2023 | 11am-12pm PT
Justine W. Welsh, MD, Associate Professor, Department of Psychiatry and Behavioral Sciences, Emory University School of Medicine
The objectives of the presentation are to 1) Describe a decreasing trend in buprenorphine prescribing for youth with opioid use disorder (OUD) 2) Recognize attitudes/beliefs among addiction treatment providers towards medication for OUD in youth 3) Propose new areas of research to increase utilization of MOUD across treatment settings.
Join the Zoom Session Here
New from the ATTC Network
 Addressing Alcohol Use Disorder in African American Youth by Faith Adams and Dr. Traci Murray. ATTC Messenger, February 2023.
ATTC's Pearls of Wisdom: Investing Soundly By Building the Substance Use Disorder Workforce by Nancy Roget, MS and Cindy Juntunen, PhD (Mountain Plains ATTC). ATTC/NIATx Service Improvement Blog. |
News from the Northeast Node
Northeast Node Science Series welcomed Dr. Craig Rush to review the science of stimulant use disorder treatment
On February 9, the Northeast Node welcomed Dr. Craig R. Rush of the University of Kentucky to present to the Science Series on treatments for stimulant use disorder. Dr. Rush’s presentation, “Treating Stimulant Use Disorders in the Context of the Opioid Crisis: A Review” gave an in-depth review of the pharmacological research to treat stimulant use disorder. While there is no FDA-approved pharmacotherapy for the treatment of stimulant use disorders, several medications have shown promising early results and are worthy of further study. The striking increase in stimulant-involved overdose deaths suggests that we need to be bold and innovative to find an effective medication to treat this condition. The recorded presentation is available to all on the Northeast Node’s website.
On Thursday, April 6, 2023 (12-1pm ET), the Science Series will welcome Eva Quirion, PhD, APRN, FNP-BC, to discuss the science and practice of extended-release buprenorphine.
Please email Northeast.Node.CTN@Dartmouth.edu to join the Science Series or Northeast Node mailing lists to stay in the know about the Science Series. |
· · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · ·
· · · · · · · · · · · · · · · · · · · · · · ·
New in the CTN Dissemination Library
 Suicidality as a Predictor of Overdose Among Patients with Substance Use Disorders. Horigian VE, et al. Journal of Clinical Medicine 2022;11(21):6400. (CTN-0037, 0049, 0051, 0053, 0054, 0064, 0067, 0068)
Care Facilitation Advances Movement Along the Hepatitis C Care Continuum for Persons with Human Immunodeficiency Virus, Hepatitis C, and Substance Use: A Randomized Clinical Trial (CTN-0064). Metsch LR, et al. Open Forum Infectious Diseases 2021;8(8):ofab334. (CTN-0064)
Cannabis and Nicotine Co-Use Among Primary Care Patients in a State with Legal Cannabis Access. McClure EA, et al. Addictive Behaviors 2023;140:107621. (CTN-0077-Ot)
Trajectories of Depression Among Patients in Treatment for Opioid Use Disorder: A Growth Mixture Model Secondary Analysis of the XBOT Trial. Vest N, et al. American Journal on Addictions 2023 (in press). (CTN-0051)
Training Needs of Practice Facilitators When Implementing An Opioid Improvement Initiative in Primary Care. Parchman ML, et al. Research Square 2021 (preprint server; not peer-reviewed). (CTN-0091)
Strategies of Managing Repeated Measures: Using Synthetic Random Forest to Predict HIV Viral Suppression Status Among Hospitalized Persons with HIV. Liu J, et al. AIDS and Behavior 2023 (in press). (CTN-0049, CTN-0064)
Research Brief: Relative Effectiveness of Social Media, Dating Apps, and Information Search Sites in Promoting HIV Self-testing: Observational Cohort Study (CTN-0083). Stafylis C, et al. Lebanon, NH: Center for Technology and Behavioral Health, Winter 2023, 1p. (CTN-0083)
Design of a Pragmatic Clinical Trial to Improve Screening and Treatment for Opioid Use Disorder in Primary Care. Rossom RC, et al. Contemporary Clinical Trials 2023;124:107012. (CTN-0095)
· · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · ·
· · · · · · · · · · · · · · · · · · · · · · ·
NIDA Job Postings: NIDA Program Official/Program Specialist & Two Contractor Positions
 NIDA is hiring for this new program, named American Indian and Alaska Native Collective Research Effort to Enhance Wellness Program (AIAN CREW).
In brief, the NIH HEAL Initiative is funding a program to support Tribes and American Indian/Alaska Native (AI/AN) serving organizations and communities to respond to the opioid/drug overdose crisis by establishing or expanding research infrastructure and capacity for Tribal research entities to conduct research related to all facets of the opioid/overdose crisis, including substance misuse, mental health related factors, and the management of pain. It will address data insufficiencies by providing support to improve data and surveillance of factors that contribute to the opioid/drug overdose crisis at the local level (including local data and connections to state, regional and national data. Increasing research capacity will include supporting the conduct of Tribally or community prioritized research. There will also be funding for technical assistance and provide support for the development of any needed partnerships to achieve all program goals. A Tribal Consultation informed the development of this effort.
NIDA is hiring staff for this research effort:
· · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · ·
· · · · · · · · · · · · · · · · · · · · · · ·
New from NIDA Director Nora Volkow
Pregnant People with Substance Use Disorders Need Treatment, Not Criminalization
Dr. Volkow recently published a piece in STAT about the need for support for pregnant people and new parents with substance use disorders -- not criminalization. Columbia University researchers recently reported that drug overdose deaths among pregnant and postpartum people increased by 81% between 2017 and 2020. In September 2022, the CDC reported that 23% of deaths during pregnancy or in the year following are related to mental health conditions, including substance use disorders.
These stunning data highlight just how important it is to ensure access to substance use disorder treatment for pregnant and postpartum people, including the need to eliminate barriers that interfere with this treatment.
Read the full STATNews piece here. |
Upcoming Events
4th Annual NIH HEAL Initiative Investigator Meeting
February 21-22, 2023 | hybrid event
This meeting will include panels, scientific symposia, discussion groups, networking, and poster sessions for in-person and virtual attendees, sharing research findings, exploring trends, and identifying opportunities to advance the initiative's goals.
2023 Annual Meeting: American Psychiatric Association
May 20-24, 2023 | San Francisco, CA
With 600+ educational sessions, 50+ topics and 20+ paid courses, APA’s 2023 Annual Meeting is the best place to connect with colleagues, learn the latest in effective clinical practice and research advancements, and earn up to 43 AMA PRA Category 1 Credit(TM).
Find more upcoming events at the NIDA website.
|
   
|
